Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics' stock has experienced significant volatility over the past year, with a decline of 83.87% but also recent gains, showing a 72.09% gain over the last six months. Key events impacting the stock price include positive Phase 1b data for NMRA-511 in Alzheimer's disease agitation, prioritization of NMRA-215 for obesity, analyst upgrades and price target increases from several financial firms, upcoming milestones with multiple clinical data readouts expected, and a downgrade from JPMorgan Chase & Co.

Neumora Therapeutics, Inc. does not experience demand seasonality in the traditional sense for its products and services. The demand for its future products will be driven by the prevalence of the diseases it targets and the successful development, regulatory approval, and commercialization of its drug candidates. The need for effective treatments is constant rather than seasonal.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company operates within the Health Care sector, specifically in the Biotechnology: Biological Products industry, and employs a precision medicine approach, integrating data science and neuroscience to target novel mechanisms of action for central nervous system diseases. Neumora's therapeutic pipeline includes Navacaprant (NMRA-140) for major depressive disorder, NMRA-511 for agitation associated with dementia due to Alzheimer's disease, NMRA-266 for schizophrenia and other neuropsychiatric disorders, NMRA-NMDA for schizophrenia, NMRA-CK1d for amyotrophic lateral sclerosis, NMRA-NLRP3 for certain neurodegenerative conditions with obesity as a lead indication, NMRA-GCase for Parkinson's disease, NMRA-861, and NMRA-094 for low arousal threshold-obstructive sleep apnea.

Neumora Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States, and focuses on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.

Neumora Therapeutics has cultivated a reputation as a company focused on addressing the global brain disease crisis by developing targeted and effective precision medicines. The company's reputation has been influenced by positive clinical trial results, analyst sentiment, and its focus on unmet needs. Recent positive developments and analyst sentiment suggest a strengthening reputation within the biopharmaceutical and investment communities.

Neumora Therapeutics, Inc. has a mixed ownership structure, including institutional, retail, and individual investors. Institutional investors hold approximately 18.69% to 54.57% of the company's stock, while insiders hold a significant portion, around 26.8% to 65.90% of the shares. Major institutional owners include Softbank Group Corp, MIC Capital Management UK LLP, Siren, L.L.C., Vanguard Group Inc, Fmr Llc, WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST, ICONIQ Capital, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Lunate Capital Ltd, Millennium Management Llc, and Amgen Inc. Among individual owners, Kristina Burow and Paul Berns are major shareholders.